Studies with the schistosomicide oxamniquine (UK-4271). I. Activity in rodents and in vitro.
D000284:Administration, Oral; D000351:Africa, Eastern; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D002681:China; D006224:Cricetinae; D003470:Culture Media; D007273:Injections, Intramuscular; D007928:Lethal Dose 50; D008099:Liver / Q000382:microbiology; D008154:Lucanthone / Q000627:therapeutic use; D008642:Mesenteric Veins / Q000382:microbiology; D051379:Mice; D009549:Nigeria; D009560:Niridazole / Q000627:therapeutic use; D009574:Nitro Compounds / Q000627:therapeutic use; D011437:Propylamines / Q000627:therapeutic use; D011647:Puerto Rico; D011804:Quinolines / Q000627:therapeutic use*; D012548:Schistosoma haematobium; D012550:Schistosoma mansoni; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000008:administration & dosage / Q000627:therapeutic use
D000871:Anthelmintics; D003470:Culture Media; D009574:Nitro Compounds; D011437:Propylamines; D011804:Quinolines; D012556:Schistosomicides; D008154:Lucanthone; D009560:Niridazole